Most Read

Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialise axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases. Axatilimab is an

Pfizer has dosed the first subjects in a Phase I clinical trial to test an influenza vaccine which is developed using mRNA technology. The randomised Phase I trial,

The US Food and Drug Administration (FDA) has approved Amgen’s Repatha (evolocumab) to treat paediatric patients aged ten years and above with heterozygous familial hypercholesterolemia (HeFH). The drug received approval as

The World Health Organization (WHO) has added Regeneron Pharmaceuticals and Roche’s Covid-19 antibody drug cocktail to the list of treatments for Covid-19 patients. The agency has recommended the

AstraZeneca has entered a strategic, long-term research collaboration with biopharmaceutical firm VaxEquity to discover, develop and commercialise self-amplifying RNA (saRNA) therapeutics platform. VaxEquity was founded last year by

Tonix Pharmaceuticals has expanded its research partnership with Columbia University in the US for the development of tailored Covid-19 vaccines and treatments with precision medicine. The move follows

Canadian biotechnology firm AbCellera has signed a collaboration and licence agreement with Everest Medicines to advance new antibody therapies. Under the multi-year agreement, Everest will obtain rights to

The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a booster dose of Pfizer-BioNTech’s Covid-19 vaccine. The regulatory agency approved the booster dose

German pharmaceutical firm Boehringer Ingelheim has acquired Abexxa Biologics to expand its research efforts in cancer immunology and novel immunotherapeutic approaches. The financial details of the transaction were